DGX vs PRVA
As of Sep 20, 2026, Quest Diagnostics (DGX) scores 6.8/10 and Privia Health Group (PRVA) 3.6/10 on AlphaStocks' five-model composite, so DGX scores higher. DGX trades 24% above its model fair value.
DGX
QUEST DIAGNOSTICS INC
6.8
Consider Buy
$246.52
PRVA
Privia Health Group, Inc.
3.6
Weak
$19.84
DGX vs PRVA: Which is the Better Investment?
QUEST DIAGNOSTICS INC (DGX) scores 6.8/10 while Privia Health Group, Inc. (PRVA) scores 3.6/10 on AlphaStocks' composite model. QUEST DIAGNOSTICS INC has the higher composite rating of Consider Buy. On a P/E basis, QUEST DIAGNOSTICS INC trades at 28.1x, making it the more attractively priced of the two.
This comparison is algorithmically generated and is not financial advice.
| Metric | DGX | PRVA |
|---|---|---|
| Scores & Fundamentals | ||
| Composite Score | 6.8/10▲ | 3.6/10 |
| Rating | Consider Buy▲ | Weak |
| Price | $246.52 | $19.84 |
| P/E Ratio | 28.1▲ | 111.6 |
| ROE | 13.8%▲ | 3.2% |
| Market Cap | $28B | $3B |
| Fair Value | $199.57 | — |
| Dividend Yield | 1.5% | — |
| Sector Rank | #19 of 168▲ | #146 of 168 |
| Model Verdicts | ||
| Piotroski | Strong▲ | Attractive |
| Buffett | Attractive▲ | Neutral |
| Graham | Caution | Caution |
| Lynch | Neutral | Attractive▲ |
| Greenblatt | Attractive▲ | Limited Data |
Related comparisons
DGX vs PRVA: Which Stock Scores Higher?
QUEST DIAGNOSTICS INC (DGX) and Privia Health Group, Inc. (PRVA) are both in the Health Care sector. DGX currently leads with a composite score of 6.8/10 (Consider Buy) compared to PRVA's 3.6/10 (Weak).
The AlphaStocks composite score evaluates each stock across four dimensions: Quality (business strength measured by Piotroski F-Score and Buffett quality criteria), Value (discount to intrinsic worth using Graham, Lynch, and Greenblatt models), Momentum (6-month price trend), and Timing (a confirmation signal that requires both value and momentum to align). A higher composite score indicates stronger overall fundamentals combined with favorable market conditions.
This comparison uses the same scoring framework for both companies, ensuring an apples-to-apples evaluation. Scores are recalculated daily after market close using data from SEC filings and market prices. Read the full methodology to understand how each model contributes to the composite score.
Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer